Note: The data shared here is as of June 25, 2026. For the latest figures, please do your own research or reach out to FinancialBeings directly with any questions.
Our Residual Income Model (RIM), based on current operating performance, indicates an UNH Stock Intrinsic Value of ~$205-243 per share (base case: 5.5-6.5% historical ReOI growth) and a no-growth floor of ~$147. Given the current price of $404, the verdict is clear: UNH is priced above its base-case fair value. The market is implying ≈7.9% perpetual growth, which is higher than what UNH has historically experienced.
Intrinsic value estimates for UNH vary wildly from $324 to $626, with no ranking page explaining the $302 spread. That is due to one source of confusion: discounted cash flow (DCF) models that are filled with guesswork. In this article, I put together a list of all public estimates, expose the weaknesses of the DCF approach, and provide a more grounded answer using a residual income framework.
UNH is in the middle of a turbulent earnings reset, driven by Medicare Advantage (MA) margin compression, the 2025 CEO transition, and an ongoing Department of Justice (DOJ) investigation into MA billing. These headwinds have brought RNOA down from over 20% pre-2025 to around 11.1% today, which is a crucial factor for any fair valuation.
UNH Stock Intrinsic Value Snapshot
| Metric | Value | Note |
| Price | $404 (as of Jun 24, 2026) | As of date; moves daily |
| 52-Week Range | $234.60 – $415.98 | Recent low-high band |
| Market Cap | ≈ $367B | Shares × price |
| Shares Outstanding | ≈ 908M (Q1 2026 10-Q) | Latest 10-Q filing |
| FY2026 Adj. EPS Guidance | ≥ $18.25 | Latest guidance release |
| Q1 2026 Adj. EPS (Actual) | $7.23 (beat ≈10%) | Beat analyst estimates |
| Forward P/E | ≈ 22× (FY26); ≈ 19× NTM | Price ÷ FY EPS |
| Dividend | $2.32/qtr; ≈ 2.3% yield | Quarterly payout |
| Analyst Consensus / Target | Buy / ≈ $407 avg (28+ analysts) | 12-month price target |
| FinancialBeings RIM Value | ≈ $205–$243 base (5.5–6.5% growth; floor ≈ $147) | Current operating performance; no DCF guesswork |
| Verdict | Above Base — price implies ≈7.9% growth | Above UNH’s own 5.5–6.5% historical norm |
What ‘Intrinsic Value’ Means for UNH and Why It Differs from Share Price
Intrinsic value is the current value of the cash flows or profits that a business can generate during its life, regardless of how investors feel about it. The share price, on the other hand, is determined by the timing of the trade, depending on the momentum, headlines and macro factors.
This is particularly significant for UNH at this moment. The stock traded above $600 in late 2024 but sold off to a 52-week low of $234.60 — driven by the DOJ probe, MA margin compression, and leadership uncertainty — before recovering to around $404 today. There is a lot of noise in that, and a fundamentals-based model cuts through it.
Two areas in particular that are of special interest to healthcare payers, such as UNH, are the medical loss ratio (MLR) — the share of premium dollars paid out in claims — and CMS reimbursement rates for Medicare Advantage. Earnings can be squeezed quickly by an unexpected jump in MLR, as happened in 2024–2025. These structural dynamics must be considered in any credible valuation.
Key Operating & Financial Metrics
The table below shows UNH’s core operating metrics sourced from SEC filings and UNH Investor Relations.
| Metric | Value | Context |
| Revenue (TTM / FY2025) | $449.7B TTM / $447.6B FY2025 | Largest health insurer by revenue |
| Free Cash Flow (TTM) | ≈ $18.1B FCFE / $23.5B FCFF | OCF minus capital expenditures |
| ROE (DuPont TTM) | 11.4% | Down from ~20%+ pre-2025 reset |
| RNOA (FY2025) | 11.1% | RIM engine; was ~20%+ pre-2025 |
| ROIC / ROTC (TTM) | ≈ 10.1% | Different sources may conflict — verify method |
| Book Value of Equity | $100.1B | Core RIM input (FY2025) |
| Net Operating Assets (NOA) | $150.4B | Core RIM input (FY2025) |
| Cost of Equity (Hurdle) | ≈ 9.3% | Model discount rate assumption |
| Q1 2026 MCR | 83.9% | Improved YoY as 2026 rate increases took hold |
UNH Intrinsic Value: Every Estimate Compared
The table below summarises UNH intrinsic value estimates and our Residual Income Model. The range ($324 to $626) captures the core problem with DCF-based models.
| Source | Method | Value | Read / Flag |
| Morningstar | DCF (3-stage) | $427 | Fair value; “High Uncertainty” rating |
| Wall St. Consensus | Analyst 12-mo targets | ≈ $407 | Buy, 28+ analysts – a price target, not intrinsic value |
| AlphaSpread – Base | Relative / multiples | $449 | Optimistic; leans on peer multiples |
| AlphaSpread – DCF | DCF | $349 | Swings with terminal-g & discount-rate inputs |
| GuruFocus – DCF | DCF (earnings-based) | $324 | Lowest estimate; no growth credit |
| GuruFocus – GF Value | Proprietary multiples | $626 | Outlier – flag as aggressive |
| FinancialBeings – RIM | RIM (RNOA-based) | ≈ $205–$243 base | Current operating performance – no DCF guesswork; floor ≈ $147 |
Why DCF Estimates Disagree by $300+
The quality of a DCF model depends on the quality of its inputs, and for UNH, those inputs are a minefield. There are three structural weaknesses which contribute to the spread:
- Terminal value dominates. In most DCFs, often 80–95% of the calculated value is based on a terminal value (assessed at the end of 5–10 years). That figure is subject to conjecture.
- The long-term growth rate (g) is unknowable. The output can swing sharply on just a 0.5% change in g. Each model selects a different g.
- Free cash flow is negative when investing. UNH’s Optum growth needs capital. DCF models penalize this growth spending by understating value during high-reinvestment periods. Investors interested in the wider healthcare sector should also read our LLY vs ABBV vs AMGN Comparison.
Our Method: Residual Income Model (RNOA-Based)
FinancialBeings does not use a DCF. Instead, we use a Residual Income Model, also known as the Edwards–Bell–Ohlson (EBO) framework. It’s a simple formula:
Intrinsic Value = Book Value of Equity + PV of Residual Operating Income (ReOI)
Where ReOI = (RNOA − Cost of Capital) × Net Operating Assets. This firmly places valuation in terms of the business’s earnings and not a forecast that extends to eternity.
The UNH inputs to our model are:
- RNOA: 11.1% (FY2025; sustainable figure after the 2024–25 earnings reset)
- Book value of equity: $100.1B
- Net Operating Assets (NOA): $150.4B
- Required return (hurdle): ≈ 9.3%
- Net debt (deducted): ≈ $50.3B over 908M shares
The result: at UNH’s historical 5.5%–6.5% ReOI growth, intrinsic value is roughly $205–$243/share; with no growth, the floor is about $147/share. At today’s $404 price, the market is pricing in ≈7.9% perpetual ReOI growth — higher than UNH has historically delivered.
Financial Beings Valuation Lens
RIM Sensitivity Analysis: What Growth Rate Justifies $404?
Intrinsic values and expected returns vary with the assumed perpetual ReOI growth rate; the table below shows them at a 9.0% hurdle rate.
| Growth (g) | Intrinsic Value ($B) | Value / Share ($) | Value / Price (%) |
|---|
Value / Price > 100% = model value exceeds the current price – a margin of safety. Value / Price < 100% = the current price exceeds model value – you are paying up for growth. Value / Price = 100% = model value equals the $404 price at the assumed growth rate.
At 2% growth, fair value is just $157.57 (39% of price). Across UNH’s historical 5.5–6.5% band the model lands at $205–$243 (51–60%) – well below today’s $404. At 7% the curve reaches $275.97 (68%), and only at 8% does intrinsic value finally clear the price at $441.73 (109%, ~9% upside).
The convex hockey-stick is the whole point: near the 9% hurdle rate, small upgrades to the growth assumption translate into outsized swings in value. The market-implied breakeven is ~7.9% – the perpetual ReOI growth UNH must sustain to justify $404, materially above its own 5.5–6.5% norm.
Net read: Under the 9.0% hurdle, UNH’s value crosses 100% of price at ~7.9% ReOI growth. Below it the stock trades above intrinsic value (base case sits at just 51–60%); a margin of safety appears only once growth clears the ~7.9% breakeven – at 8% the model prints $441. At $404 the market is capitalizing UNH for ~8% sustained ReOI growth – a demanding hurdle against an RNOA that has reset from ~20% to ~11%. The MA margin path and the DOJ overhang are the swing factors that decide whether that growth is deliverable.
| Growth (g) | Intrinsic Value ($B) | Price / Share ($) | Value / Price (%) | Expected Return (%) |
| 2% | 193.37 | 157.57 | 38.99% | 5.27% |
| 3% | 200.54 | 165.47 | 40.95% | 5.90% |
| 4% | 210.57 | 176.52 | 43.68% | 6.54% |
| 5% | 225.62 | 193.09 | 47.78% | 7.18% |
| 5.5% | 236.38 | 204.94 | 50.72% | 7.50% |
| 6.0% | 250.71 | 220.72 | 54.62% | 7.82% |
| 6.5% | 270.78 | 242.83 | 60.09% | 8.14% |
| 7% | 300.89 | 275.97 | 68.29% | 8.46% |
| 8% | 451.42 | 441.73 | 109.31% | 9.10% |
Key Drivers of UNH's Intrinsic Value
1. Medicare Advantage: Membership & Margin Recovery
UNH remains the top MA insurer at ≈26% market share, though it has shed more than 530,000 members since February 2025, when its share peaked near 29%. Q1 2026 MCR improved to 83.9%, a sign margins are stabilising as 2026 CMS rate increases and operational changes take hold. Whether this recovery is durable is the single most important variable for near-term RNOA, and therefore for intrinsic value. For a detailed peer comparison, read our UNH vs ELV Stock Comparison 2026.
2. Optum: The Services Flywheel
UNH's differentiated growth engine is Optum (Health, Rx, Insight), a vertically integrated services platform that offers pricing power and margin mix improvement over time. Management expects to achieve long-term EPS growth of about 13–16%, supported by Optum's growth. EPS guidance of ≥$18.25 implies ≈12% growth vs. FY2025's $16.35.
3. DOJ Investigation - The Tail Risk
UNH is still under criminal and civil DOJ probes for Medicare Advantage billing practices as of June 2026, which appear to have reached Optum Rx and physician compensation agreements. No charges have been filed, and UNH is cooperating. The RIM framework treats this as a cost-of-capital risk (lifting the hurdle rate), not a cash-flow scenario. This situation is moving quickly and should be re-checked as it develops.
Is UNH Undervalued or Overvalued Right Now?
Bull Case
Buybacks and dividend yield of ≈2.3% offer a solid capital return; forward P/E of ≈22× is fair versus 5-year average of ≈18–20× with the mix shift at Optum; margin recovery at MA underway; durable and deep services moat; FY2026 EPS guidance implies ≈12% growth.
Bear Case
Beyond the unquantifiable legal risk of the DOJ probe, MA membership is still in decline, MLR may be structurally higher, leadership/governance changes add uncertainty, and $404 needs ReOI growth of more than 8%, well above historical levels.
The Verdict
Fair value at UNH's historical 5.5–6.5% ReOI growth is about $205–$243/share. At $404, the price sits above that range and implies roughly 7.9% perpetual growth. Only ReOI growth above ≈8% would create a margin of safety (→ ≈$441, a 9% upside). UNH is a quality franchise, but at this price you are betting on above-normal growth. The question is whether the three growth levers — recovering RNOA, Optum expansion, and MA normalisation — can push durable growth beyond 8%. The DOJ overhang is the key swing factor. For more options in the healthcare sector, check our ranking of Best Large Healthcare Companies in 2026.
Intrinsic Value vs. Analyst Price Targets vs. Market Price
There are three different ideas that financial media often mix up:
- The intrinsic value of our RIM is ≈$205–$243/share (base case). A long-term valuation of the business based on the value of its earnings today.
- The average price target from analysts is approximately $407 (28+ analysts). A 12-month tactical call that is based on near-term earnings and relative valuation. It is not an intrinsic value.
- Market price: $404. What buyers and sellers will transact at today, reflecting both fundamentals and sentiment.
The sell-side 12-month view is already priced in with the analyst consensus target ($407) almost equal to the current price ($404). Our RIM intrinsic value, by contrast, is ≈$205–$243, based on a longer horizon and fundamentals. The difference between them is the premium the market is paying for above-normal growth expectations and sentiment.
Final Thoughts
We estimate UNH's intrinsic value at $205–$243 (historical 5.5–6.5% ReOI growth, with a no-growth floor of ≈$147), against a current market price of $404. The stock is priced for above-normal ReOI growth of ~7.9% in perpetuity, which assumes a full recovery in Medicare Advantage margins, an accelerating Optum contribution, and a clean resolution of the DOJ investigation. For a detailed long-term outlook, read our UNH 5-Year Stock Forecast.
The single variable to watch: can UNH grow ReOI above ~8%? That is possible if MA margins return to normal and Optum keeps growing at double-digit rates. The longer the DOJ investigation drags on, or MLR stays structurally high, the harder it is to justify today's $404 price.
Monitor RNOA trend per quarter. If RNOA rebounds, so will intrinsic value. Looking for more value opportunities? Check our list of Best Stocks Under $20 Right Now
Disclaimer. For informational purposes only. Not investment advice. Always verify data against primary sources before making financial decisions.
FAQ
Is UNH stock undervalued right now?
Not on its track record. At UNH's historical 5.5–6.5% ReOI growth, fair value is about $205–$243 — below the ~$404 price, which embeds ~7.9% perpetual growth. The stock is priced for growth above its own norm; a margin of safety appears only if growth sustains above ~8% (≈$441).
What is the fair value estimate for UnitedHealth (UNH)?
Our base-case fair value is about $205–$243 per share — UNH's historical 5.5–6.5% ReOI growth at a 9% hurdle rate, with a ~$147 no-growth floor. Third-party estimates split: $324–$370 on an earnings basis and $427–$626 on multiples. The wide gap is the tell that growth assumptions, not facts, drive the headline numbers.
Why do UNH valuations range so widely?
Most use discounted cash flow, which is highly sensitive to two estimates: the long-term growth rate and the discount rate. Nudge either one and the output swings by hundreds of dollars, which is why estimates range from ≈$324 to ≈$626. A residual income model built on a company's current performance sidesteps most of that guesswork.
Why use a residual income model instead of a DCF for UNH?
A residual income model values UNH from what it has already earned — current book value plus profit above its cost of capital — rather than speculative future growth. Anchoring on today's earnings, which UNH has just reset, is a much more solid basis than a forecast-based DCF.
How do analysts value UNH?
Chiefly discounted cash flow with a forward P/E check. The Wall Street consensus is a Buy, with an average 12-month target near $407 from 28+ analysts. Remember that a price target is a 12-month tactical call, not an intrinsic value — we instead anchor on a residual income model (≈$200).
What most affects UNH’s intrinsic value?
Four levers: the Medicare Advantage margin path, the medical loss ratio, Optum's growth and the DOJ/regulatory outcome. The first three feed RNOA — the engine of residual income — while regulatory risk raises the cost of capital. Restore margins and RNOA, and intrinsic value climbs back toward, and above, the price.
Is UNH a good long-term investment at current prices?
It is a quality franchise priced for a recovery. At its historical 5.5–6.5% growth, UNH is worth ~$205–$243; at ~$404, the market is paying for ~7.9% growth, above that norm. A margin of safety needs ReOI growth above ~8% (≈$441, +9%). The swing factor is whether RNOA recovers from ~11% toward its ~20% history. This is analysis, not investment advice.
References
- AlphaSpread. (2026). UNH intrinsic value summary. AlphaSpread. View Source
- Centers for Medicare & Medicaid Services. (2026). Medicare Advantage and Part D contract and enrollment data. U.S. Department of Health and Human Services. View Source
- GuruFocus. (2026). UNH intrinsic value - DCF and GF Value. GuruFocus. View Source
- Morningstar. (2026). UnitedHealth Group Inc (UNH) fair value estimate. Morningstar. View Source
- StockAnalysis. (2026). UNH forecast and estimates. StockAnalysis. View Source
- U.S. Securities and Exchange Commission. (2026). UnitedHealth Group Inc - EDGAR filings (10-K, 10-Q, 8-K). SEC EDGAR. View Source
- UnitedHealth Group. (2026). Q1 2026 earnings release and investor presentation. UnitedHealth Group Investor Relations. View Source
- UnitedHealth Group. (2025). Annual report (FY2025 10-K). UnitedHealth Group Investor Relations. View Source
